ATOSSA THERAPEUTICS INC (ATOS) Stock Analyst Earnings Estimates
NASDAQ:ATOS - Nasdaq - US04962H5063 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 40K | 6.222M -100.00% | 56M | 141.1M 151.96% | 220.87M 56.53% | 353.96M 60.26% | 779.87M 120.33% | 688.09M -11.77% | ||||||||||||
| EBITDA YoY % growth | -9.26M | -13.671M -34.88% | -7.58M 44.36% | -7.841M -1.58% | -13.186M -61.33% | N/A -51.19% | N/A 15.45% | N/A -40.80% | N/A -35.02% | N/A -13.27% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -9.82M | -14.193M -29.94% | -6.083M 43.18% | -7.967M 0.83% | -13.02M -58.97% | -18.666M -51.09% | -15.333M 15.40% | -22.095M -40.45% | -28.388M -34.94% | -31.828M -13.32% | -28.771M 8.31% | -33.556M -16.63% | -41.107M -22.50% | -3.118M 92.42% | 38.408M 1,331.89% | 90.696M 136.14% | 183.15M 101.94% | 567.67M 209.95% | 506.84M -10.72% | |
| Operating Margin | -24,550.00% | -228.11% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -5.57% | 27.22% | 41.06% | 51.74% | 72.79% | 73.66% | |
| EPS YoY % growth | N/A | -88.13 4.00% | -31.46 64.31% | -11.20 64.40% | -5.13 57.59% | -2.07 56.41% | -1.23 4.86% | -0.19 90.86% | -0.22 -16.67% | -0.24 -28.57% | -0.22 18.15% | -0.28 -24.61% | -0.32 -14.81% | 0.08 124.74% | 0.53 571.45% | 0.86 63.11% | 1.44 68.45% | 4.26 195.41% | 2.62 -38.52% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.06 28.23% | -0.07 -32.60% | -0.07 -32.60% | -0.07 -19.00% | -0.06 5.26% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -7.905M 12.35% | -7.854M -12.52% | -8.16M -14.85% | -8.517M -33.39% | -8.16M -3.23% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.06 -20.00% | -0.06 | 0.00 | -3.80% |
| Q2 2024 Q2Q % growth | -0.05 37.50% | -0.06 | 0.01 | 13.50% |
| Q1 2024 Q2Q % growth | -0.05 | -0.07 | 0.02 | 26.47% |
| Q4 2023 Q2Q % growth | -0.09 -50.00% | -0.06 | -0.03 | -55.70% |
| Q3 2023 Q2Q % growth | -0.05 16.67% | -0.07 | 0.02 | 29.97% |
| Q2 2023 Q2Q % growth | -0.08 -60.00% | -0.06 | -0.02 | -30.72% |
| Q1 2023 Q2Q % growth | -0.05 -25.00% | -0.06 | 0.01 | 18.30% |
| Q4 2022 Q2Q % growth | -0.06 -50.00% | -0.06 | 0.00 | 1.96% |
| Q3 2022 Q2Q % growth | -0.06 -50.00% | -0.06 | 0.00 | 1.96% |
| Q2 2022 Q2Q % growth | -0.05 16.67% | -0.06 | 0.01 | 18.30% |
| Q1 2022 Q2Q % growth | -0.04 | -0.05 | 0.01 | 21.57% |
| Q4 2021 Q2Q % growth | -0.04 95.45% | -0.05 | 0.01 | 12.85% |
| Q3 2021 Q2Q % growth | -0.04 88.24% | -0.05 | 0.01 | 12.85% |
| Q2 2021 Q2Q % growth | -0.06 86.05% | -0.04 | -0.02 | -68.07% |
| Q1 2021 Q2Q % growth | -0.04 87.50% | -0.05 | 0.01 | 21.57% |
| Q4 2020 Q2Q % growth | -0.88 -238.46% | -0.28 | -0.60 | -219.54% |
| Q3 2020 Q2Q % growth | -0.34 5.56% | -0.35 | 0.01 | 3.38% |
| Q2 2020 Q2Q % growth | -0.43 46.25% | -0.29 | -0.14 | -50.56% |
| Q1 2020 Q2Q % growth | -0.32 | -0.40 | 0.08 | 19.56% |
| Q4 2019 Q2Q % growth | -0.26 | -0.34 | 0.08 | 22.76% |
| Q3 2019 Q2Q % growth | -0.36 | -0.53 | 0.17 | 32.13% |
| Q2 2019 Q2Q % growth | -0.80 | -0.49 | -0.31 | -63.40% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -5.55% | 0% | -1.96% | 0% |
| Revenue | N/A | N/A | N/A | N/A |